New treatment reduces recurrence and improves survival in bladder cancer A combination of immunotherapy and targeted cancer treatment given before and after surgery may reduce the risk of recurrence and improve survival in patients with muscle‑invasive bladder cancer who cannot tolerate conventional chemotherapy. The findings come from a new study from Karolinska Institutet, published in The New England Journal of Medicine.

A new bladder cancer approach combining immunotherapy with targeted treatment shows reduced recurrence and improved survival. A promising step forward.
#BladderCancer #Immunotherapy #CancerResearch #TCSC
news.ki.se/new-treatmen...

#Exosomal lnc-TAF12–2:1 is upregulated in #BladderCancer, driving proliferation by sponging miR-7847–3p to stabilize ASB12; its inhibition suppresses #tumorigenesis, positioning it as a novel diagnostic and therapeutic #biomarker.

#OpenAccess: doi.org/10.1016/j.ge...

We invite submissions to the Special Collection Advances in Biomarkers for Genitourinary Cancers in Ther Adv Med Onc. We welcome studies on diagnostic, prognostic, predictive and molecular biomarkers across GU malignancies.
buff.ly/sQgaDWS
#GUcancer #Oncology #ProstateCancer #BladderCancer

We are supporting an important research study led by Birkbeck College, University of London. Researchers are looking to better understand people’s experiences of being diagnosed & treated for cancer.

Prof Anne Miles: ae.miles@bbk.ac.uk
Dr Claudia Redeker: claudia.redeker@bbk.ac.uk

#bladdercancer

Yale Launches Innovative Clinical Trial for Metastatic Bladder Cancer Yale researchers have launched an innovative study combining targeted therapy with surgery—an approach that would have been unthinkable just a few years ago.

Yale has launched an innovative trial for metastatic bladder cancer that brings surgeons, medical #oncologists and radiation specialists into one team, rather than treating each step in a silo. #BladderCancer #ClinicalTrials #TCSC
medicine.yale.edu/news-article...

Trial Tuesday! Dr. Matt Galsky of Mount Sinai Division of Gastroenterology leads Alliance A032103/MODERN trial investigating if DNA released from tumor cells into the blood helps identify the best #immunotherapy treatment after surgery for #bladdercancer. More info: https://bit.ly/Alliance-A032103

🚨 Call for Papers!
Our new Special Collection in Ther Adv Med Onc - Advances in Biomarkers for Genitourinary Cancers - is now open.
🗓 Deadline: 6 Nov 2026
🔗 Submit here: buff.ly/sQgaDWS
#Oncology #GUcancer #Biomarkers #ProstateCancer #BladderCancer #KidneyCancer

Why smoking is the top cause of bladder cancer Bladder cancer and smoking are strongly linked. Discover how tobacco toxins affect the bladder and why quitting improves survival and lowers recurrence.

“About 10 years after quitting, the risk of developing #BladderCancer is reduced by up to 50 percent. After 20-25 years, the risk approaches that of people who never smoked.”: buff.ly/iNF2Prb

from kevinmd
#smoking #cancer #smokers #cigarettes

Now enrolling! BCG (a bladder immunotherapy) is standard for non-muscle invasive bladder cancer. For cancer returned after BCG, the Alliance A032103 (GAIN) trial tests adding gemcitabine—a chemo drug—to BCG to prevent recurrence. Learn more: https://bit.ly/Alliance-GAIN-BCG #BladderCancer

🗣️ #Wolverhampton Patient Support Meeting - March 30th 🗣️

If you’re affected by #bladdercancer join us on March 30th for an informative talk on Cancer Complementary Services and Support by the Complementary Therapy Team.

⏰ 1.30pm til 3.30pm
📍 The Hub, WV11 2LH

#CancerSupport #PatientSupport

Neoadjuvant Mitomycin C Before TURBT May Cut NMIBC Recurrence, Progression Risks - Oncology Nurse Advisor A phase 2 trial evaluated the effectiveness and safety of neoadjuvant intravesical mitomycin-C instillation in patients with urothelial non-muscle invasive bladder cancer.

In #NMIBC, immediate administration of 2 doses of neoadjuvant intravesical mitomycin C chemotherapy prior to TURBT may reduce recurrence and progression risks compared with TURBT alone. From @renalurologynews.bsky.social.

https://bit.ly/41gINY2

#blcsm #bladdercancer

ASCO_GU_ 2025_Social_Media_Report.pdf drive.google.com/file/d/1Q1DrPio5c6P4F3VeL-5b3UCSo7DR9hXm/view

🚀 Dive into #ASCOGU25 buzz!

Top themes: #Efficacy 20%, #Data 19%, #ClinicalTrials 15%.

#ProstateCancer & #BladderCancer dominate, 75% positive vibes on new immunotherapy wins. 📊🩺

Download our full report http://dlvr.it/TRcw4G !

#Oncology #SocialListening #LucidQuest

Nadofaragene Firadenovec Is Added to NCCN Guidelines in BCG-Unresponsive Papillary NMIBC Without CIS | OncLive Nadofaragene firadenovec has been added to the NCCN guidelines in BCG-unresponsive papillary NMIBC without CIS.

The NCCN guidelines have now added nadofaragene firadenovec-vncg (Adstiladrin) as a category 2A recommendation for patients with BCG-unresponsive NMIBC with papillary Ta/T1 tumors without concomitant carcinoma in situ. #BladderCancer #NMIBC #oncology
🔗 Read more: www.onclive.com/view/nadofar...

New potential therapy developed in response to bladder cancer Adding an anti-inflammatory medication to immunotherapy and chemotherapy drugs may provide long-term suppression of bladder tumour growth.

Researchers have identified inflammatory signals that help bladder tumours hide from the immune system, opening the door to new combinations that may boost chemo‑immunotherapy. #BladderCancer #Immunotherapy #TCSC
www.drugtargetreview.com/news/102211/...

EA8231 Research Study for Patients With Advanced Urothelial Cancer Study chair Dr. Monika Joshi and co-chair Dr. Petros Grivas discuss this trial that aims to improve outcomes for patients with anti-PD(L)1-resistant advanced urothelial cancer.

New video: Dr. Monika Joshi & @pgrivasmdphd.bsky.social discuss the EA8231 #ClinicalTrial, which aims to evaluate and answer the critical question of #immunotherapy (anti-PD1/L1) rechallenge in #UrothelialCancer therapy. Watch here: bit.ly/47UxFnr #BladderCancer

Now on demand: Expert insights on managing BCG-unresponsive #NMIBC and new bladder-sparing treatments.
Explore clinical strategies to help improve outcomes and preserve quality of life.

Watch now ➡️ bit.ly/4shPKUS

#Urology #BladderCancer #CME #NMIBC #MedicalEducation

#Targetome
TGFβ3 drives bladder cancer metastasis through succinate metabolism and stromal remodeling, with L-chicoric acid blocking this pathway 🧬🎯
Details: www.maxapress.com/article/doi/10.48130/tar...
#bladdercancer #remodeling #acid #cancermetastasis

The #OncoAlertColloquium 2026 GU Malignancies🚨 #EAU26
Presentation by Dr. Tom Powles: Year in Review in #BladderCancer
WATCH HERE👉 vimeo.com/1160841460?s...

Tom Powles 2025 year-in-review highlights real progress—and ongoing challenges—in Bladder Cancer

J&J says Inlexzo follow-up 'promising' in bladder cancer Johnson & Johnson says localised delivery of its FGFR inhibitor erdafitinib could provide the first targeted treatment for early‑stage bladder cancer.

#JohnsonandJohnson has revealed early clinical data with a new formulation of its #FGFRinhibitor erdafitinib that suggests it could become the first targeted treatment for early‑stage #bladdercancer.

pharmaphorum.com/news/jj-says...

Ipilimumab and Nivolumab With CRT May Be a Bladder-Sparing Treatment in MIBC - Oncology Nurse Advisor The phase 2, single-arm INDIBLADE trial assessed induction ipilimumab plus nivolumab followed by CRT in patients with MIBC.

Combined neoadjuvant treatment with ipilimumab and nivolumab followed by CRT shows promise as a bladder-sparing treatment for muscle-invasive #bladdercancer. From @natmed.nature.com and @renalurologynews.bsky.social.

Read more: ➡️ https://bit.ly/3MZPjiH

#MIBC #blcsm #UroOnc

Bladder cancer: treatment and risk of metastasis #bladder #bladdercancer #oncology #metastasis Bladder cancer: treatment and risk of metastasis #bladder #bladdercancer #oncology #metastasis

Bladder cancer: treatment and risk of metastasis #bladder #bladdercancer #oncology #metastasis ... Continue to: www.facebook.com/reel/1855406...

3 Cases ➡️ The therapeutic potential of sequential use of ADC containing the same chemotherapeutic reagents with different targets for metastatic urothelial cancer.

🔓journals.sagepub.com/share/DUJJCIRFYH7VFMXEDN...

#bladdercancer #CanSky #OncoSky

BCAN Summit 2026! #bladdercancer #bladdercancerwarrior #advocacy #bcan

Smartwatches coming of age Volume 13, Issue 10 | March 12, 2026

ALSO IN THIS ISSUE

A blood test that could let you keep your bladder
To diagnose disease, could we just follow the energy?

open.substack.com/pub/sensitiv...

#sensitiveandspecific #diagnostics #smartwatch #wearabledevice #healthmonitoring #healthscreening #afib #hypertension #bladdercancer

ASCO_GU_ 2025_Social_Media_Report.pdf drive.google.com/file/d/1Q1DrPio5c6P4F3VeL-5b3UCSo7DR9hXm/view

🚀 Dive into #ASCOGU25 buzz!

Top themes: #Efficacy 20%, #Data 19%, #ClinicalTrials 15%.

#ProstateCancer & #BladderCancer dominate, 75% positive vibes on new immunotherapy wins. 📊🩺

Download our full report http://dlvr.it/TRRj7w !

#Oncology #SocialListening #LucidQuest

HealtheVoices Advisory Panel 2026! #bladdercancer #bladdercancerwarrior #advocacy #johnsonandjohnson #healthevoices

Management of high-risk NMIBC is evolving beyond BCG alone.

Get practical insights on immunotherapy plus BCG, including key clinical evidence and strategies for managing patients in everyday practice.

👉 Access the program: bit.ly/3MT4yKg

#NMIBC #BladderCancer #Urology

The cover of The Lancet Primary Care February 2026 issue, featuring a pharmacist helping an older patient with their prescription.

Our new issue is out now 🎉

We feature research on #bladdercancer, routine testing for detection of #syphilis, and point-of-care testing strategies for #antibioticprescribing for respiratory tract infections, and more!

Explore and download the issue on our journal homepage: hubs.li/Q03yqV6c0.

Urothelial cancer is the most common type of #bladdercancer. The EA8192 study is evaluating durvalumab and chemotherapy for patients with high grade upper tract urothelial cancer prior to nephroureterectomy. bit.ly/ea8192-trial

Dr Galsky on the Design of the KEYNOTE-B15 Trial in MIBC | OncLive Matthew D. Galsky, MD, unpacks the design of the phase 3 KEYNOTE-B15 in patients with MIBC.

📹 @mattgalsky.bsky.social of @mountsinainyc.bsky.social unpacks the design of the phase 3 KEYNOTE-B15 in patients with MIBC. #oncology #medtwitter #MIBC #bladdercancer
Watch here: www.onclive.com/view/dr-gals...